Enliven Therapeutics, Inc. (NASDAQ:ELVN)
| Market Cap | $3.59B+121.1% |
| Revenue (ttm) | $0 |
| Net Income | -$113.48M-16.7% |
| EPS | -$1.68+8.7% |
| Shares Out | 73.60M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 972,564 |
| Open | $48.10 |
| Previous Close | $48.31 |
| Day's Range | $46.96 - $49.11 |
| 52-Week Range | $14.79 - $62.32 |
| Beta | 0.24 |
| Analysts | Buy |
| Price Target | $76.29(+56.33%) |
| Earnings Date | Mar 2, 2027 |
About ELVN
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
3 firms rating ELVN in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Mar 2, 2027Earnings report
$ELVN stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in ELVN holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ELVN's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ELVN Estimated quarterly lobbying spending
Source: U.S. Senate LDA
ELVN Revenue by Segment
| Relcobatinib (ELVN-001) | $11.97M | 53.28% |
| Stock-based compensation | $4.78M | 21.28% |
| Other | $3.99M | 17.76% |
| ELVN-002 | $1.03M | 4.58% |
| Facilities, laboratory supplies and other | $695.00K | 3.09% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New ELVN patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ELVN from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ELVN
| VTIVanguard Morningstar Total Stock Market ETF | $96.54M |
| IWMiShares Russell 2000 ETF | $77.08M |
| VXFVanguard Extended Market ETF | $32.99M |
| IWOiShares Russell 2000 Growth ETF | $28.17M |
| IBBiShares Biotechnology ETF | $23.95M |
| DFASDimensional - US Small Cap ETF | $16.83M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from ELVN’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Insider Score Trend Over Time
-33.0 since Aug 21Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| CANC | Tema Oncology ETF | 2.72% |
| XPH | State Street SPDR S&P Pharmaceuticals ETF | 1.76% |
| BBC | Virtus Biotech Clinical Trials ETF | 0.82% |
| MEDI | Harbor Health Care ETF (MEDI) | 0.82% |
| IHE | iShares U.S. Pharmaceuticals ETF | 0.66% |
| DWAS | Invesco Dorsey Wright SmallCap Momentum ETF | 0.43% |
| FTXH | First Trust Nasdaq Pharmaceuticals ETF | 0.41% |
| TDNA | T. Rowe Price Biotech ETF | 0.40% |
| ACSG | American Century Small Cap Growth Insights ETF | 0.32% |
| ESSC | Eventide Small Cap ETF | 0.29% |
| PILL | Direxion Daily Pharmaceutical & Medical Bull 3X ETF | 0.25% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 0.24% |
Weight is the stock’s share of each fund’s holdings.